AmCad BioMed Corp

AmCad BioMed Corp has a current ratio of 22.62, indicating strong liquidity with a high proportion of current assets relative to current liabilities. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. However, the company reported negative operating and net income, with operating income at -TWD 87,932,000 and net income at -TWD 55,719,000, reflecting a challenging profitability position. The company's return on equity (ROE) is -10.69%, and return on assets (ROA) is -8.95%, both significantly below the industry norms for profitable medical equipment firms. These metrics indicate that the company is not generating returns that meet the expectations of its equity and asset base, which is a concern for investors. AmCad BioMed Corp's revenue is primarily derived from the sale of its advanced medical devices, with no disclosed segment or geographic breakdown in the provided data. The company operates in both domestic and international markets, but the extent of geographic diversification is not specified. The lack of detailed segment data limits the ability to assess the company's exposure to specific markets or product lines. The company's revenue for the latest period is TWD 30,437,000, and while the outlook for the current and next fiscal years is not provided, the negative operating and net income suggest a need for significant improvement in revenue growth or cost management to achieve profitability. The company's free cash flow is negative at -TWD 56,749,000, indicating that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs. The risk assessment for AmCad BioMed Corp indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's negative operating and net income, along with its negative free cash flow, suggest that it may face challenges in maintaining its current financial position without external financing or operational improvements. The company's dilution potential is currently low, but this could change if it needs to raise additional capital to fund operations or growth initiatives. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial snapshot and risk assessment do not mention any recent events that would impact its operations or financial health. The absence of recent events or significant changes suggests a stable but unremarkable period for the company.